Patients with Pancreatic Cancer May Live Longer with Surgery Alone – With a Catch
Surgery Alone May Extend Life for Select Pancreatic cancer Patients
Table of Contents
For patients diagnosed with early-stage pancreatic cancer, surgical removal of the tumor-without the addition of chemotherapy-may offer a meaningful survival advantage, according to research presented October 24, 2024, at the American College of Surgeons Clinical Congress. However, this benefit is highly dependent on the specific characteristics of the tumor and the patientS overall health.
Pancreatic cancer is notoriously challenging to treat, with a five-year survival rate of just 11%, according to the American Cancer Society. Often, the diagnosis comes late in the disease process, when the cancer has already spread. This new research focuses on a subset of patients with resectable tumors – those that can be surgically removed – and offers a possibly less aggressive treatment pathway for some.
The study’s Findings
Researchers analyzed data from a large, international registry of patients who underwent surgery for pancreatic cancer. The study,involving over 600 patients,revealed that those with tumors less than 2 centimeters in size,confined to the pancreas,and without lymph node involvement experienced improved overall survival when they did not receive adjuvant chemotherapy following surgery. specifically, the median overall survival was approximately 5.6 years for this group compared to 3.1 years for those who underwent chemotherapy after surgery.
“This is a significant finding as chemotherapy can have substantial side effects,” explains Dr. Marco Del Chiaro, a surgical oncologist at Memorial Sloan Kettering Cancer Center, who was not involved in the study. “If we can identify patients who are unlikely to benefit from chemotherapy and spare them those toxicities, it would be a major step forward.”
Who Benefits Most?
The study highlights the importance of precise tumor characterization. patients who benefited most from surgery alone had tumors classified as stage IA, meaning they were small, localized, and hadn’t spread to nearby lymph nodes. The research team used detailed pathological analysis to determine these characteristics.
However,the researchers cautioned that not all patients with early-stage disease are the same. Factors such as the patient’s age, performance status (overall health), and the presence of other medical conditions also play a role in treatment decisions.A multidisciplinary team, including surgeons, oncologists, and radiologists, should carefully evaluate each patient’s individual case.
The ‘Catch’ and Future Directions
The study also revealed that patients with certain high-risk features, even within the early-stage group, still benefited from chemotherapy. These features included the presence of perineural invasion (cancer cells around nerves) or lymphatic invasion (cancer cells in lymphatic vessels).
“This research underscores the need for personalized medicine in pancreatic cancer treatment,” says Dr. Eileen Park, a gastroenterologist at the university of California, San Francisco.”We need to move away from a one-size-fits-all approach and tailor treatment to the individual characteristics of each patient’s tumor and their overall health.”
Researchers are now working to develop more elegant biomarkers – measurable indicators of cancer - that can definately help predict which patients are most likely to benefit from chemotherapy and which can safely avoid it. Ongoing clinical trials are also investigating the role of targeted therapies and immunotherapies in the treatment of pancreatic cancer. The hope is that these advances will lead to improved outcomes and a better quality of life for patients facing this challenging disease.